medigraphic.com
Revista Médica Sinergia

2019, Número 12

<< Anterior Siguiente >>

Revista Médica Sinergia 2019; 4 (12)


Actualización en esófago de Barrett

Elizondo VJR, Chaverri PG, Téllez VI

Idioma: Español
Referencias bibliográficas: 15
Paginas: 304
Archivo PDF: 143.87 Kb.


RESUMEN

El esófago de Barrett (BE) es una de las enfermedades gastroenterológicas más frecuentes, como consecuencia del reflujo gastroesofágico crónico, provoca lesiones en el epitelio esofágico normal, el cual es reemplazado por mucosa metaplasica, siendo esta más resistente al reflujo, pero causando predisposición a adenocarcinoma esofágico.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus. American Journal of Gastroenterology. 2016 01;111(1):30- 50. https://doi.org/10.1038/ajg.2015.322

  2. Que J, Garman KS, Souza RF, Spechler SJ. Pathogenesis and Cells of Origin of Barrett's Esophagus. Gastroenterology. 2019 08;157(2):349-364.e1. https://doi.org/10.1053/j.gastro.2019.03.072

  3. R. MAR, G. FF. ESÓFAGO DE BARRETT: REVISIÓN DE LA LITERATURA. Revista Médica Clínica Las Condes. 2015 09;26(5):557-564. https://doi.org/10.1016/j.rmclc.2015.09.002

  4. Kramer JR, Fischbach LA, Richardson P, Alsarraj A, Fitzgerald S, Shaib Y, Abraham NS, Velez M, Cole R, Anand B, Verstovsek G, Rugge M, Parente P, Graham DY, El–Serag HB. Waist-to-Hip Ratio, but Not Body Mass Index, Is Associated With an Increased Risk of Barrett's Esophagus in White Men. Clinical Gastroenterology and Hepatology. 2013 04;11(4):373-381.e1. https://doi.org/10.1016/j.cgh.2012.11.028

  5. Singh S, Garg SK, Singh PP, Iyer PG, El-Serag HB. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and metaanalysis. Gut. 2013 Nov 12;63(8):1229-1237. https://doi.org/10.1136/gutjnl-2013-305997

  6. Tan MC, El-Serag HB, Yu X, Thrift AP. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans. Alimentary Pharmacology & Therapeutics. 2018 06 29;48(4):469-477. https://doi.org/10.1111/apt.14895

  7. Hu Q, Sun T, Hong J, Fang J, Xiong H, Meltzer SJ. Proton Pump Inhibitors Do Not Reduce the Risk of Esophageal Adenocarcinoma in Patients with Barrett’s Esophagus: A Systematic Review and Meta- Analysis. Lynch JP. PLOS ONE. 2017 01 10;12(1):e0169691. https://doi.org/10.1371/journal.pone.0169691

  8. Jankowski J, de Caestecker J, Love S, Reilly G, Watson P, Sanders S. Esomeprazole and aspirin in Barrett’s oesophagus (AspECT): a randomised factorial trial. The Lancet. Jul,2018;(392):400-408. https://doi.org/10.1016/S0140-6736(18)31388-6

  9. Masclee GMC, Coloma PM, Spaander MCW, Kuipers EJ, Sturkenboom MCJM. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study. BMJ Open. 2015 01 29;5(1):e006640- e006640. https://doi.org/10.1136/bmjopen-2014-006640

  10. Whiteman DC, Kendall BJ. Barrett's oesophagus: epidemiology, diagnosis and clinical management. Medical Journal of Australia. 2016 Oct;205(7):317-324. https://doi.org/10.5694/mja16.00796

  11. Wani S, Rubenstein JH, Vieth M, Bergman J. Diagnosis and Management of Low-Grade Dysplasia in Barrett’s Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association. Gastroenterology. 2016 Nov;151(5):822- 835. https://doi.org/10.1053/j.gastro.2016.09.040

  12. Phoa KN, van Vilsteren FGI, Weusten BLAM, Bisschops R, Schoon EJ, Ragunath K, Fullarton G, Di Pietro M, Ravi N, Visser M, Offerhaus GJ, Seldenrijk CA, Meijer SL, ten Kate FJW, Tijssen JGP, Bergman JJGHM. Radiofrequency Ablation vs Endoscopic Surveillance for Patients With Barrett Esophagus and Low-Grade Dysplasia. JAMA. 2014 03 26;311(12):1209. https://doi.org/10.1001/jama.2014.2511

  13. Haidry RJ, Butt MA, Dunn JM, Gupta A, Lipman G, Smart HL, Bhandari P, Smith L, Willert R, Fullarton G, Di Pietro M, Gordon C, Penman I, Barr H, Patel P, Kapoor N, Hoare J, Narayanasamy R, Ang Y, Veitch A, Ragunath K, Novelli M, Lovat LB. Improvement over time in outcomes for patients undergoing endoscopic therapy for Barrett's oesophagus-related neoplasia: 6-year experience from the first 500 patients treated in the UK patient registry. Gut. 2014 Dec 24;64(8):1192-1199. https://doi.org/10.1136/gutjnl-2014-308501

  14. Evans JA, Early DS, Chandraskhara V, Chathadi KV, Fanelli RD, Fisher DA, Foley KQ, Hwang JH, Jue TL, Pasha SF, Sharaf R, Shergill AK, Dominitz JA, Cash BD. The role of endoscopy in the assessment and treatment of esophageal cancer. Gastrointestinal Endoscopy. 2013 03;77(3):328- 334. https://doi.org/10.1016/j.gie.2012.10.001

  15. Phoa KN, Pouw RE, Bisschops R, Pech O, Ragunath K, Weusten BLAM, Schumacher B, Rembacken B, Meining A, Messmann H, Schoon EJ, Gossner L, Mannath J, Seldenrijk CA, Visser M, Lerut T, Seewald S, ten Kate FJ, Ell C, Neuhaus H, Bergman JJGHM. Multimodality endoscopic eradication for neoplastic Barrett oesophagus: results of an European multicentre study (EURO-II). Gut. 2015 03 02;65(4):555- 562. https://doi.org/10.1136/gutjnl-2015-309298




2020     |     www.medigraphic.com